Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?

Thumbnail Image

Files

Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors.pdf (1.45 MB)

Embargo End Date

ICR Authors

Larkin, James

Authors

Sugiyama, K
Gordon, A
Popat, S
Okines, A
Larkin, J
Chau, I

Document Type

Journal Article

Date

2025-02-01

Date Accepted

2024-12-18

Abstract

Pathological response (PR) is an oncological outcome measure that indicates the therapeutic response to neoadjuvant therapy. In clinical trials involving neoadjuvant or perioperative interventions, overall survival and disease/event-free survival are typically the primary outcome measures. Although some evidence suggests that pathological complete response (pCR) can serve as a surrogate marker for the primary endpoint in prospective trials, it remains uncertain whether pCR is a true surrogate marker for patients with cancer undergoing curative resection across all solid tumours. Here, we review the role of PR as a surrogate marker and its associated methodological issues in the era of perioperative immune checkpoint inhibitors.

Citation

ESMO Open, 2025, 10 (2), pp. 104122 -

DOI

10.1016/j.esmoop.2024.104122

URI

https://repository.icr.ac.uk/handle/internal/7311

Rights

https://creativecommons.org/licenses/by-nc-nd/4.0/

Source Title

ESMO Open

Publisher

ELSEVIER

ISSN

2059-7029

eISSN

2059-7029

Collections

Clinical Studies

Research Team


 Directorate Clin Studies

Notes